肠道菌群调节肿瘤化疗的疗效及毒性的研究进展

Current overviews in the efficacy and toxicity of gut microbiota in regulating tumor chemotherapy

肠道菌群调节宿主对化疗药物的反应主要表现在促进药物疗效和减轻毒性反应,即可以通过靶向肠道菌群的方式提高化疗效果和降低化疗毒性。因此,肠道菌群对于临床个体化肿瘤治疗策略的发展至关重要。基于大量的临床、动物和体外研究的结果,发现肠道菌群不但与化疗的药理作用密切相关,还与肿瘤靶向免疫治疗密切相关。本文概述了药物微生物学在肿瘤化疗与免疫治疗中的意义,并总结了在临床实践中通过改善微生物群来提高疗效和减少毒性反应的措施,以期为制定合理的临床用药方案提供一定的参考。

Gut microbiota regulates host responses to chemotherapeutic drugs mainly by promoting drug efficacy and reducing toxic reactions. In other words, the effect and toxicity of chemotherapy can be improved and reduced by targeting gut microbiota. Therefore, gut microbiota is critical for the development of clinically individualized cancer treatment strategies. This view is based on the results of numerous clinical, animal, and in vitro studies, which shows that gut microbiota is closely related to the pharmacological effects of not only chemotherapy but also tumor targeted immunotherapy. In this review, we summarized the significance of pharmaco-microbiology in cancer chemotherapy, and summarized the measures to increase the efficacy and reduce toxic reactions by improving the microbiota in clinical practice, in order to provide some references for the development of reasonable clinical drug regimen.